[Methotrexate and 5-fluorouracil with leucovorin therapy in advanced gastric cancer: the enhancement of 5-fluorouracil antitumor activity by leucovorin]. 1987

I Sugiura, and T Ogasawara, and T Kinoshita, and Y Ono, and T Onizuka, and K Nagata, and O Kamiya, and K Ohara, and A Hoshino

UI MeSH Term Description Entries
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002955 Leucovorin The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. Calcium Leucovorin,Citrovorum Factor,Folinic Acid,N(5)-Formyltetrahydrofolate,5-Formyltetrahydrofolate,5-Formyltetrahydropteroylglutamate,Calcium Folinate,Folinic Acid-SF,Leucovorin, (D)-Isomer,Leucovorin, (DL)-Isomer,Leucovorin, (R)-Isomer,Leucovorin, Calcium (1:1) Salt,Leucovorin, Calcium (1:1) Salt, (DL)-Isomer,Leucovorin, Calcium (1:1) Salt, Pentahydrate,Leucovorin, Monosodium Salt,Leukovorin,Leukovorum,Wellcovorin,5 Formyltetrahydrofolate,5 Formyltetrahydropteroylglutamate,Acid, Folinic,Factor, Citrovorum,Folinate, Calcium,Folinic Acid SF,Leucovorin, Calcium,Monosodium Salt Leucovorin
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

I Sugiura, and T Ogasawara, and T Kinoshita, and Y Ono, and T Onizuka, and K Nagata, and O Kamiya, and K Ohara, and A Hoshino
July 1993, Cancer,
I Sugiura, and T Ogasawara, and T Kinoshita, and Y Ono, and T Onizuka, and K Nagata, and O Kamiya, and K Ohara, and A Hoshino
April 2003, Cancer research and treatment,
I Sugiura, and T Ogasawara, and T Kinoshita, and Y Ono, and T Onizuka, and K Nagata, and O Kamiya, and K Ohara, and A Hoshino
January 1995, Anticancer research,
I Sugiura, and T Ogasawara, and T Kinoshita, and Y Ono, and T Onizuka, and K Nagata, and O Kamiya, and K Ohara, and A Hoshino
September 2003, Nihon rinsho. Japanese journal of clinical medicine,
I Sugiura, and T Ogasawara, and T Kinoshita, and Y Ono, and T Onizuka, and K Nagata, and O Kamiya, and K Ohara, and A Hoshino
January 1994, European journal of cancer (Oxford, England : 1990),
I Sugiura, and T Ogasawara, and T Kinoshita, and Y Ono, and T Onizuka, and K Nagata, and O Kamiya, and K Ohara, and A Hoshino
January 2000, Neoplasma,
I Sugiura, and T Ogasawara, and T Kinoshita, and Y Ono, and T Onizuka, and K Nagata, and O Kamiya, and K Ohara, and A Hoshino
January 1990, European journal of cancer (Oxford, England : 1990),
I Sugiura, and T Ogasawara, and T Kinoshita, and Y Ono, and T Onizuka, and K Nagata, and O Kamiya, and K Ohara, and A Hoshino
November 1993, International journal of oncology,
I Sugiura, and T Ogasawara, and T Kinoshita, and Y Ono, and T Onizuka, and K Nagata, and O Kamiya, and K Ohara, and A Hoshino
June 1992, Journal of chemotherapy (Florence, Italy),
I Sugiura, and T Ogasawara, and T Kinoshita, and Y Ono, and T Onizuka, and K Nagata, and O Kamiya, and K Ohara, and A Hoshino
March 1998, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!